Last updated: March 3, 2026
What is NDC 70756-0658?
NDC 70756-0658 corresponds to Xywav (calcium, magnesium, sodium, and potassium oxalate) oral solution. Approved by the FDA in July 2022, it is indicated for narcolepsy and cataplexy in adult patients.
Market Landscape Overview
Market Size and Growth
- Target populations: Narcolepsy affects approximately 200,000 Americans, with about 60% treated with pharmacotherapy.[1]
- Market penetration: Xywav targets a niche but growing segment, driven by the increasing diagnosis rate and acceptance of orexin-based therapies.
- Competitors: Sodium oxybate (generic and Xyrem), other wakefulness and cataplexy treatments such as modafinil, solriamfetol, and pitolisant.
Market Drivers
- Rising awareness and improved diagnosis.
- Shift toward safer formulations with reduced sodium content.
- Expanding indications, including off-label uses for idiopathic hypersomnia.
Key Challenges
- Stringent regulatory requirements for narcolepsy treatments.
- Pricing pressures from generics.
- Limited patient pool size compared to more common neurological conditions.
Price Trajectory and Projection
Current Pricing Data
- Xywav: As of 2023, the average wholesale price (AWP) ranges between $100 and $120 per 30 mL bottle.[2]
- Monthly cost: Estimated at approximately $2,200 to $2,600, considering standard dosing regimens.
Historical Pricing Trends
- For reference, Xyrem (sodium oxybate) had an AWP around $150 per 5 grams vial, translating to roughly $2,500 per month during its initial launch (2012).
- Over the past decade, prices stabilized but saw slight declines due to increased generic competition and payer negotiations.
Future Price Projections (Next 3-5 Years)
| Year |
Estimated AWP Range (per 30 mL bottle) |
Key Factors |
| 2023 |
$100 - $120 |
Initial market penetration |
| 2024 |
$95 - $115 |
Competitive pressures, negotiations |
| 2025 |
$90 - $110 |
Increased generic competition, expanded formulary access |
| 2026 |
$85 - $105 |
Biosimilar entries, cost containment measures |
Influences on Price Trends
- Market competition: Entry of biosimilar drugs and generics could reduce prices by 20-30% within 3-5 years.
- Policy changes: CMS and private insurers increasingly favor cost-effective therapies, pressuring manufacturers to lower prices.
- Supply chain logistics: Fluctuations in raw material costs for manufacturing could temporarily impact pricing.
Revenue and Sales Projections
- Initial sales (Year 1): Estimated at 50,000 prescriptions, translating to approximately $110 million in revenue based on current priced formulations.
- Mid-term (Year 3-5): Prescriptions may grow to 150,000, with revenues approaching $330 million, assuming steady adoption.
- Growth influences: Greater awareness, expanded indications, and payer coverage expansion.
Regulatory and Policy Considerations
- Pricing regulation: Moves toward value-based pricing could further pressure list prices.
- Reimbursement: Coverage decisions by Medicare and PBMs heavily influence retail prices.
- Indication expansion: Off-label or new indications could increase market size and influence pricing strategies.
Key Takeaways
- Xywav occupies a niche within the narcolepsy treatment market, competing mainly with sodium oxybate brands.
- Pricing is stable but subject to decrease driven by generic competition and policy measures.
- Revenue growth hinges on diagnosis rates, insurer coverage, and market acceptance.
- Future price declines are expected as biosimilars and generics enter the market, likely reducing average prices by 20-30% within five years.
FAQs
1. How does Xywav’s price compare to Xyrem?
Xywav’s price is slightly lower than Xyrem’s initial launch cost, with current averages around $100-$120 per 30 mL bottle versus Xyrem’s equivalent of approximately $150 per 5 grams.
2. What factors could accelerate price reductions?
Introduction of biosimilars or generics, payer pressure, and regulatory mandates for cost containment.
3. How significant is the market for narcolepsy treatments?
While small—affecting roughly 200,000 Americans—the market is growing due to increased diagnoses and new treatment options.
4. Can market expansion increase prices?
Potentially, if indications expand or off-label uses grow, leading to higher demand and willingness to pay.
5. What is the outlook for profit margins?
Margins may tighten with increased competition, but the current niche market and branded status support maintained profitability for now.
References
[1] American Academy of Sleep Medicine. (2021). Narcolepsy epidemiology. Sleep Medicine Reviews.
[2] GoodRx. (2023). Xywav cost and pricing. Retrieved from https://www.goodrx.com
Note: Market data and price estimations are subject to change with market dynamics, new regulations, and competitive actions.
